Literature DB >> 21514492

Children's perceptions of influenza illness and preferences for influenza vaccine.

Emuella M Flood1, Stan L Block, Matthew C Hall, Matthew D Rousculp, Victoria M Divino, Seth L Toback, Parthiv J Mahadevia.   

Abstract

INTRODUCTION: In this qualitative study we explored children's perceptions of influenza, preferences for influenza vaccines, and ability to understand "risk" of vaccine adverse effects and different attributes between injectable and intranasal vaccines.
METHOD: In-person, semi-structured interviews were conducted among 28 U.S. children aged 6 through 12 years.
RESULTS: Many children understood the concept of influenza illness and believed vaccination was important. Efficacy, adverse effects, and mode of administration affected their preferences for influenza vaccines. Children 8 years of age and older were able to consider multiple attributes when selecting between hypothetical vaccines, and their responses were consistent with their previously stated preferences for individual attributes. Most children would prefer a nasal spray over a shot vaccine when all other vaccine attributes were equal. DISCUSSION: Efficacy, adverse effects, and mode of administration were important factors in children's preferences for influenza vaccine. Children as young as 8 years of age appeared to understand vaccine "risk" and were able to consider multiple attributes simultaneously when choosing between vaccine alternatives.
Copyright © 2011 National Association of Pediatric Nurse Practitioners. Published by Elsevier, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21514492     DOI: 10.1016/j.pedhc.2010.04.007

Source DB:  PubMed          Journal:  J Pediatr Health Care        ISSN: 0891-5245            Impact factor:   1.812


  7 in total

1.  Does Choice of Influenza Vaccine Type Change Disease Burden and Cost-Effectiveness in the United States? An Agent-Based Modeling Study.

Authors:  Jay V DePasse; Kenneth J Smith; Jonathan M Raviotta; Eunha Shim; Mary Patricia Nowalk; Richard K Zimmerman; Shawn T Brown
Journal:  Am J Epidemiol       Date:  2017-05-01       Impact factor: 4.897

2.  Focusing on flu: Parent perspectives on school-located immunization programs for influenza vaccine.

Authors:  Amy B Middleman; Mary B Short; Jean S Doak
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

3.  Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium.

Authors:  Laetitia Gerlier; Mark Lamotte; Sofia Dos Santos Mendes; Oliver Damm; Markus Schwehm; Martin Eichner
Journal:  Paediatr Drugs       Date:  2016-08       Impact factor: 3.022

4.  Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study.

Authors:  Jay V DePasse; Mary Patricia Nowalk; Kenneth J Smith; Jonathan M Raviotta; Eunha Shim; Richard K Zimmerman; Shawn T Brown
Journal:  Vaccine       Date:  2017-06-09       Impact factor: 3.641

5.  Potential Consequences of Not Using Live Attenuated Influenza Vaccine.

Authors:  Kenneth J Smith; Mary Patricia Nowalk; Angela Wateska; Shawn T Brown; Jay V DePasse; Jonathan M Raviotta; Eunha Shim; Richard K Zimmerman
Journal:  Am J Prev Med       Date:  2017-04-18       Impact factor: 5.043

6.  Procedural and Physical Interventions for Vaccine Injections: Systematic Review of Randomized Controlled Trials and Quasi-Randomized Controlled Trials.

Authors:  Anna Taddio; Vibhuti Shah; C Meghan McMurtry; Noni E MacDonald; Moshe Ipp; Rebecca Pillai Riddell; Melanie Noel; Christine T Chambers
Journal:  Clin J Pain       Date:  2015-10       Impact factor: 3.442

7.  Intranasal Human Growth Hormone (hGH) Induces IGF-1 Levels Comparable With Subcutaneous Injection With Lower Systemic Exposure to hGH in Healthy Volunteers.

Authors:  Andrew L Lewis; Faron Jordan; Tina Patel; Kirk Jeffery; Gareth King; Martin Savage; Stephen Shalet; Lisbeth Illum
Journal:  J Clin Endocrinol Metab       Date:  2015-10-01       Impact factor: 5.958

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.